Animal Model News and Research

RSS

Scientists discover new mechanism of H5N1 circulation and transmission in nature

A team of scientists, led by Mauro Delogu, virologist from the Veterinary Faculty of the Bologna University and researchers from the Istituto Superiore di Sanit-, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia and St. Jude Children's Research Hospital (Memphis, Tennessee) have discovered a new way of avian influenza transmission.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Study on effects of resveratrol on metabolism of microcebus murinus

Resveratrol is a natural substance that is widely studied, for its anti-ageing properties among other things. For the first time, work by a team in the "Mécanismes adaptatifs : des organismes aux communautés" Laboratory (CNRS/Muséum National d'Histoire Naturelle) has revealed that this compound reduces weight gain in lemurs. Such findings provide new information regarding the effects of resveratrol on energy metabolism and the control of body mass in primates. They may give a clearer understanding of the factors that govern obesity in humans. This study is published on 22 June 2010 in /BMC Physiology/.

25 Jun 2010

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

A new animal model of atherosclerosis has allowed researchers to identify a host of genes turned on or off during the initial stages of the process, before a plaque appears in the affected blood vessel.

24 Jun 2010

UCSD researchers awarded $2.5M CIRM grant to explore stem cells

A pair of University of California San Diego researchers - Martin Marsala, a specialist in spinal cord trauma and disorders, and Yang Xu, an immunologist - have been awarded more than $2.5 million in new grants from the California Institute for Regenerative Medicine.

24 Jun 2010

Abusive attachments during infancy have negative consequences in social behavior development

In a new Biological Psychiatry article, Dr. Regina Sullivan and colleagues have dissected the behavior of mother rats and their infant pups, modeling nurturing by stroking and abuse with electric shock. In this animal model of infant abuse, they took into consideration the unique infant neurobehavioral learning attachment system that ensures infant rats' attachment to their caregiver regardless of the quality of care received.

23 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

SCS may be able to modulate PD symptoms: Study

A new study from Rhode Island Hospital indicates that spinal cord stimulation may be able to modulate Parkinson's disease symptoms. The lead author will present the findings at the 2010 American Society for Stereotactical and Functional Neurosurgery Biennial Meeting, June 14-16 in New York City.

15 Jun 2010

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.

15 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

Sialidase improves nerve regrowth, motor recovery and nervous system function: Researchers

Once damaged, nerves in the spinal cord normally cannot grow back and the only drug approved for treating these injuries does not enable nerve regrowth. Publishing online this week in the Early Edition of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine show that treating injured rat spinal cords with an enzyme, sialidase, improves nerve regrowth, motor recovery and nervous system function.

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

A rare but fatal disease of blood vessels in the lung may be caused in part by aberrant silencing of genes rather than genetic mutation, new research reports. Pulmonary arterial hypertension, a syndrome characterized by gradual blockage of blood vessels in the lungs, has been linked to genetic causes in a small percentage of patients. But University of Chicago researchers have now found that a form of epigenetics - the modification of gene expression - causes the disease in an animal model and could contribute to the disease in humans.

8 Jun 2010

Lovastatin protects animals against plague

An experimental study has revealed that lovastatin, a drug prescribed for the treatment of hypercholesterolemia, protects animals against the deadly effects of plague. This infectious disease is on the upsurge in parts of the world. These results obtained by scientists at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (CNRS/Université Aix-Marseille 2) have been published in the journal PLoS ONE.

4 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

Commonalities between flies and humans make valuable new model for galactosemia

Galactosemia is a metabolic disease resulting from an inherited defect that prevents the proper metabolism of galactose, a sugar commonly found in dairy products, like milk. Exposure of affected people to galactose, can damage most of their organ systems and can be fatal. The ability to study the disease is limited by a lack of animal models.

1 Jun 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Research findings offer possible applications in diagnosis and treatment of patients with atherosclerosis

Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.

26 May 2010